Clinical features in different age groups of patients with autoimmune hepatitis

Peng,Milin; Li,Yi; Zhang,Min; Jiang,Yongfang; Xu,Yuan; Tian,Yi; Peng,Feng; Gong,Guozhong

doi:10.3892/etm.2013.1363

2014-January Volume 7 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

2014-January Volume 7 Issue 1

Full Size Image

Article

Clinical features in different age groups of patients with autoimmune hepatitis

Authors:
- Milin Peng
- Yi Li
- Min Zhang
- Yongfang Jiang
- Yuan Xu
- Yi Tian
- Feng Peng
- Guozhong Gong
View Affiliations / Copyright

Affiliations: Center of Liver Diseases, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China
Pages: 145-148
|
Published online on: October 25, 2013

https://doi.org/10.3892/etm.2013.1363
Expand metrics +

Abstract

The Chinese population are at an increased risk of autoimmune hepatitis (AIH). The aims of this study were to determine the demographic and clinical features of AIH in China. A total of 83 patients with AIH diagnosed by the revised scoring system were re‑analyzed, and the clinical presentations among the different ages were compared. The patients were classified according to age at presentation. AIH occurred in patients aged ≤30 years (9.6%), 31‑39 years (10.8%), 40‑49 years (16.9%), 50‑59 years (31.3%) and ≥60 years (31.3%). There were no differences in the form of the clinical presentation, concurrent autoimmune diseases, cirrhosis distribution and autoantibodies among the groups. However, patients aged ≥60 years presented with higher levels of alkaline phosphatase (ALP) and γ‑glutamyl transpeptidase (γ‑GT) compared with patients aged ≤30 years (P=0.034, P=0.043, respectively), and patients aged 31‑39 years had a significantly lower immunoglobulin G (IgG) level compared with those aged 50‑59 years (P=0.049) and those aged ≥60 years (P=0.012). By contrast, patients aged ≤30 years had a significantly higher total bilirubin (TBIL) level compared with those aged 31‑39 years (P=0.007), 50‑59 years (P=0.002) and ≥60 years (P=0.013). A substantial portion of patients with AIH were aged >60 years, indicating a poor liver‑associated outcome under current management strategies. Elderly patients appeared to be more asymptomatic compared with the younger patients.

View Figures

View References

1	Alvarez F, Berg PA, Bianchi FB, et al: International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 31:929–938. 1999. View Article : Google Scholar : PubMed/NCBI
2	Seo S, Toutounjian R, Conrad A, et al: Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol. 23:1410–1414. 2008. View Article : Google Scholar : PubMed/NCBI
3	Czaja AJ: Autoimmune liver disease. Curr Opin Gastroenterol. 19:232–242. 2003. View Article : Google Scholar
4	Wiesner RH, Demetris AJ, Belle SH, et al: Acute allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 28:638–645. 1998. View Article : Google Scholar : PubMed/NCBI
5	Feld JJ, Dinh H, Arenovich T, et al: Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 42:53–62. 2005. View Article : Google Scholar : PubMed/NCBI
6	Czaja AJ: Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol. 51:313–333. 2005.PubMed/NCBI
7	Floreani A, Niro G, Rosa Rizzotto E, et al: Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 24:1051–1057. 2006. View Article : Google Scholar : PubMed/NCBI
8	Parker DR and Kingham JG: Type I autoimmune hepatitis is primarily a disease of later life. QJM. 90:289–296. 1997. View Article : Google Scholar : PubMed/NCBI
9	Ichai P, Duclos-Vallée JC, Guettier C, et al: Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 13:996–1003. 2007. View Article : Google Scholar : PubMed/NCBI
10	Johnson PJ and McFarlane IG: Meeting report: International Autoimmune Hepatitis Group. Hepatology. 18:998–1005. 1993. View Article : Google Scholar : PubMed/NCBI
11	Ngu JH, Gearry RB, Frampton CM, et al: Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology. 55:522–529. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hoeroldt B, McFarlane E, Dube A, et al: Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 140:1980–1989. 2011. View Article : Google Scholar : PubMed/NCBI
13	Manns MP, Woynarowski M, Kreisel W, et al: Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 139:1198–1206. 2010. View Article : Google Scholar : PubMed/NCBI
14	Al-Chalabi T, Underhill JA, Portmann BC, et al: Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol. 6:1389–1395. 2008. View Article : Google Scholar
15	Ngu JH, Gearry RB, Frampton CM and Stedman CA: Predictors of poor outcome in patients with autoimmune hepatitis: A population-based study. Hepatology. 57:2399–2406. 2013. View Article : Google Scholar : PubMed/NCBI
16	Czaja AJ and Carpenter HA: Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 43:532–538. 2006. View Article : Google Scholar : PubMed/NCBI
17	Miyake Y, Iwasaki Y, Takaki A, et al: Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis. Intern Med. 46:1945–1949. 2007. View Article : Google Scholar : PubMed/NCBI
18	Czaja AJ: Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 30:394–401. 1999. View Article : Google Scholar : PubMed/NCBI
19	Baeres M, Herkel J, Czaja AJ, et al: Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 51:259–264. 2002. View Article : Google Scholar : PubMed/NCBI
20	Zauli D, Ghetti S, Grassi A, et al: Anti-neutrophil cytoplasmic antibodies in type 1 and type 2 autoimmune hepatitis. Hepatology. 25:1105–1107. 1997. View Article : Google Scholar : PubMed/NCBI
21	Czaja AJ, Donaldson PT and Lohse AW: Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol. 97:413–419. 2002. View Article : Google Scholar : PubMed/NCBI
22	Toda G, Zeniya M, Watanabe F, et al: Present status of autoimmune hepatitis in Japan - correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol. 26:1207–1212. 1997. View Article : Google Scholar : PubMed/NCBI
23	Czaja AJ and Freese DK; American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 36:479–497. 2002. View Article : Google Scholar
24	Krawitt EL: Autoimmune hepatitis. N Engl J Med. 354:54–66. 2006. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Clinical features in different age groups of patients with autoimmune hepatitis

This article is mentioned in:

Abstract

Figure 1

Related Articles